View in EDS PDF Full Text

Hierro en etapa preoperatoria y la transfusión en pacientes sometidas a histerectomía.

Saved in:
Bibliographic Details
Title: Hierro en etapa preoperatoria y la transfusión en pacientes sometidas a histerectomía.
Alternate Title: Iron in pre-operative stage and transfusion in patients undergoing hysterectomy.
Authors: Campos-Aguirre, Esmeralda1 esmeralda.campos@imss.gob.mx, Bravo-Acevedo, Alicia2, Benitez-Arvizu, Gamaliel1
Source: Revista Medica del IMSS. 2023 Supplement 2, pS453-S459. 7p.
Subjects: IRON supplements, BLOOD transfusion, HYSTERECTOMY, UTERINE fibroids, TREATMENT effectiveness, ANEMIA, UTERINE myomectomy
Abstract (English): Background: The correction of preoperative anemia is part of the patient blood management program, in order to improve the patient's clinical results by reducing the number of transfusions in surgery. Uterine fibroids can cause anemia, so the application of iron before hysterectomy could reduce transfusion. Objective: To evaluate the impact of iron treatment in the preoperative stage on the need for transfusion in patients with anemia secondary to myomatosis in the trans and postoperative stage of hysterectomy. Material and methods: Patients with uterine myomatosis who presented with microcytic anemia in the preoperative stage were included; clinical records were reviewed, the clinical characteristics of the population were obtained; The patients were distributed into two study groups according to whether or not they had received iron treatment; the outcome variable was the transfusion of packed erythrocytes in the first 7 days after surgery. Results: 134 patients were included, with a median fibroid size of 4 cm. 21 (15.6%) patients used iron. Patients who used iron had a relative risk (RR): 0.36 (95%CI: 0.12-1.07). Delta hemoglobin < 1 g/dL, RR: 1.59 (95%CI: 0.94-2.67). Uterine fibroid size > 5cm had a RR of 1.96 (95%CI: 1.25-3.05). Conclusion: Treatment with iron in the pre-surgical stage showed a tendency to protect transfusions in the trans and post-surgical stage. The main factor related to transfusion was fibroid size > 5 cm. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introducción: la corrección de la anemia preoperatoria parte del programa de manejo hemático del paciente, a fin de mejorar sus resultados clínicos disminuyendo la cantidad de transfusiones en cirugía. La miomatosis uterina puede cursar con anemia, por lo que la aplicación de hierro antes de la histerectomía podría disminuir la transfusión. Objetivo: evaluar el impacto del tratamiento con hierro en la etapa prequirúrgica sobre la necesidad de transfusión en pacientes con anemia secundaria a miomatosis en la etapa trans y posoperatoria de histerectomía. Material y métodos: se incluyeron pacientes con miomatosis uterina que cursaron con anemia microcítica en la etapa preoperatoria; se realizó revisión de los expedientes clínicos y se obtuvieron las características clínicas de la población. Las pacientes se distribuyeron en dos grupos de estudio de acuerdo con el antecedente de haber recibido o no tratamiento con hierro. La variable de desenlace fue la transfusión de concentrados eritrocitarios en los primeros siete días a partir de la cirugía. Resultados: se incluyeron 134 pacientes, 21 (15.6%) utilizaron hierro. Las pacientes que utilizaron hierro tuvieron un riesgo relativo (RR) de 0.36 (IC95%: 0.12-1.07) para transfusión. La delta de hemoglobina < 1 g/dL tuvo un RR: 1.59 (IC95%: 0.94-2.67). El tamaño de mioma > 5 cm tuvo un RR: 1.96 (IC95%: 1.25-3.05). Conclusión: el tratamiento con hierro en etapa prequirúrgica mostró tendencia a protección para transfusiones en etapa trans y posquirúrgica. El principal factor relacionado para transfusión fue el tamaño del mioma > 5 cm. [ABSTRACT FROM AUTHOR]
Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:Background: The correction of preoperative anemia is part of the patient blood management program, in order to improve the patient's clinical results by reducing the number of transfusions in surgery. Uterine fibroids can cause anemia, so the application of iron before hysterectomy could reduce transfusion. Objective: To evaluate the impact of iron treatment in the preoperative stage on the need for transfusion in patients with anemia secondary to myomatosis in the trans and postoperative stage of hysterectomy. Material and methods: Patients with uterine myomatosis who presented with microcytic anemia in the preoperative stage were included; clinical records were reviewed, the clinical characteristics of the population were obtained; The patients were distributed into two study groups according to whether or not they had received iron treatment; the outcome variable was the transfusion of packed erythrocytes in the first 7 days after surgery. Results: 134 patients were included, with a median fibroid size of 4 cm. 21 (15.6%) patients used iron. Patients who used iron had a relative risk (RR): 0.36 (95%CI: 0.12-1.07). Delta hemoglobin < 1 g/dL, RR: 1.59 (95%CI: 0.94-2.67). Uterine fibroid size > 5cm had a RR of 1.96 (95%CI: 1.25-3.05). Conclusion: Treatment with iron in the pre-surgical stage showed a tendency to protect transfusions in the trans and post-surgical stage. The main factor related to transfusion was fibroid size > 5 cm. [ABSTRACT FROM AUTHOR]
ISSN:04435117
DOI:10.5281/zenodo.8319809